Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Andere Sprachen
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Bericht
ÜbersichtChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionen 
ÜbersichtAlle NewsAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über EISAI CO., LTD.
15.09.EISAI : To join the global emvironmental initiative 're100'
14.09.EISAI : AbbVie, Eisai, and EA Pharma Launch 'Humira Support Tool Ordering Servic..
14.09.EISAI : to Join The Global Environmental Initiative "RE100"
14.09.EISAI : TO JOIN THE GLOBAL EMVIRONMENTAL INITIATIVE “RE100”
14.09.EISAI : To present abstracts on oncology products and pipeline at esmo virtual c..
13.09.EISAI : AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Servic..
13.09.EISAI : AbbVie, Eisai, and EA Pharma Launch “Humira® Support Tool Ordering..
10.09.Japan's Nikkei 225 Up 1.3% on Outlook for Expanded Government Stimulus
10.09.Japan's Topix hits highest since 1990 on hopes of new govt, better earnings
10.09.Japan shares rally on, Topix hits over 30-year high on earnings optimism
09.09.Neuroglee Therapeutics Pte. Ltd. announced that it has received $10 million i..
07.09.CITIUS PHARMACEUTICALS : Acquires Rights to Oncology Immunotherapy E7777 From Dr..
31.08.EISAI : and FUJI YAKUHIN Conclude License Agreement Concerning the Development a..
30.08.BIOGEN : provides free Aduhelm as U.S. clinics await Medicare payment
16.08.EISAI : Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) La..
12.08.MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
12.08.EISAI : FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combinat..
12.08.EISAI : FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combin..
05.08.EISAI : Notification Regarding Revision of Consolidated Financial Forecasts for ..
05.08.EISAI : Receives award for excellence in corporate communications at the 37th co..
04.08.EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFR..
04.08.EISAI : CONSOLIDATED FINANCIAL REPORT for the Three-Month Period Ended June 30, ..
04.08.EISAI : FY 2021 (Ending March 31, 2022) First Quarter Financial Results Referenc..
04.08.Eisai Co., Ltd. Provides Dividend Guidance for the Second Quarter and the Fis..
04.08.Eisai Co., Ltd. Reports Consolidated Financial Results for the Three Months P..
04.08.Eisai Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ending March 31..
02.08.BIOGEN : and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-..
02.08.BIOGEN : Eisai Co., Ltd. - LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CL..
02.08.EISAI : Anti-epileptic drug fycompa approved in china as monotherapy for partial..
02.08.EISAI : Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial..
02.08.EISAI : Anti-epileptic drug fycompa® approved in china as monotherapy for partia..
30.07.EISAI : LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFFECTS OF L..
30.07.BIOARCTIC : Eisai presented latest data from the lecanemab clinical program at A..
30.07.EISAI : and Biogen Present Preliminary Assessment of the Clinical Effects of Lec..
30.07.EISAI : Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First..
30.07.EISAI : Biogen, Eisai report design of real-world study of Alzheimer's treatment
29.07.EISAI : Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for..
28.07.Bristol Myers sees return to growth for Opdivo, tops estimates
27.07.EISAI : Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations..
27.07.EISAI : Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presenta..
23.07.MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
23.07.EISAI : FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combinat..
21.07.Eisai to present latest data on pipeline assets in the area of alzheimer's di..
21.07.BIOGEN : Alzheimer's drug slow to take off as U.S. Medicare wrestles with covera..
21.07.EISAI : to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Dis..
21.07.EISAI : To present latest data on pipeline assets in the area of alzheimer's dis..
19.07.EISAI : Status of aduhelm in the united states
19.07.EISAI : Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
19.07.EISAI : Launches bile acid transporter inhibitor goofice® in thailand
19.07.EISAI : STATUS OF ADUHELM™ IN THE UNITED STATES
16.07.Tokyo toujours perturbée par la situation sanitaire au Japon
16.07.Nikkei dips below 28,000 as tech stocks track Nasdaq slide
16.07.Nikkei breaks below 28,000 as tech stocks track Nasdaq slide
12.07.Japanese shares rebound on growth confidence, Yaskawa's outlook
09.07.BIOGEN : FDA Approves Updated ADUHELM Prescribing Information to Emphasize Popul..
09.07.Japanese shares fall to 8-week low on growth slowdown worries
09.07.BIOARCTIC : Interim Report for the period April - June 2021
09.07.Japanese shares eye worst week in nearly 1 year on economic slowdown concerns
08.07.BIOGEN : Eisai Receives FDA Approval for Updated Label of Alzheimer's Drug Aduhe..
30.06.EISAI : Launches in-house developed anti-insomnia drug dayvigo (lemborexant) in ..
30.06.EISAI : Launches in-house developed anti-insomnia drug dayvigo® (lemborexant) in..
29.06.EISAI : Position and Policy Regarding Reduction in the Trading Unit of the Compa..
28.06.Japan's Nikkei ends flat as investors cautious ahead of U.S. data
28.06.Japan's Nikkei inches lower as chip-related stocks slip
25.06.Japan stocks track Wall Street's solid finish to close week higher
25.06.Japanese shares track Wall St higher, cautious outlook caps gains
24.06.EISAI : Shelf registration for issuance of stock options
24.06.EISAI : ANTICANCER AGENT 'TAZVERIK TABLETS 200mg' APPROVED IN JAPAN FOR EZH2 GEN..
24.06.BIOGEN : EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Des..
24.06.BIOGEN : and Eisai Update for the Alzheimers Disease Community
24.06.Tokyo boucle une séance prudente
24.06.EISAI : and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation..
24.06.Tokyo mitigée en matinée
23.06.EISAI : drug for Alzheimer's with Biogen gets breakthrough status in U.S.
23.06.BIOARCTIC : FDA grants Breakthrough Therapy designation for lecanemab in Alzheim..
1  2  3  4  5  6  7  8  9  10Weiter
Anstehende Termine für EISAI CO., LTD.